“PI3K pathway activation,” defined as two or more of the following: absent PTEN staining, phosphorylated Akt, phosphorylated S6K, and/or PIK3CA mutations, was observed in 117 out of 159 breast cancers in Study 3. This evidence concerns the gene RPS6KB1 and breast carcinoma.